Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Gap Inc (GAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Gap Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.73 (market cap $4.49B), while Gap Inc trades at $18.37 (market cap $6.86B). The key difference: Gap Inc is the larger of the two by market cap, and Gap Inc pays a 3.67% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | GAP | |
|---|---|---|
Market Cap | $4.49B | $6.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $29.13 |
52-Week Low | $20.06 | $18.68 |
Enterprise Value | $3.69B | $9.95B |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Gap trades at $19.07, down 0.94% on the day, with a bearish technical signal despite oversold RSI readings. The stock shows strong fundamentals with a P/E of 7.69, net income margin of 6.25%, and robust cash flow. Recent news highlights a turnaround in progress, with nine consecutive positive comps and AI-driven marketing initiatives, though legal investigations and Athleta's rebuild create headwinds.
The outlook is mixed: valuation metrics suggest undervaluation with a consensus price target of $27, but technical weakness and legal risks temper near-term optimism. Earnings growth and digital transformation are key catalysts, while investor sentiment remains cautious amid ongoing legal scrutiny and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
